Stockscreener 앱 받기
11.74
9.55%
-1.24
시간 외 거래:
11.45
-0.29
-2.47%
Jaguar Health Inc 주식(JAGX)의 최신 뉴스
SEC Form 424B5 filed by Jaguar Health Inc. - Quantisnow
Geode Capital Management LLC Has $98,000 Position in Jaguar Health, Inc. (NASDAQ:JAGX) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Jaguar Health (JAGX) Reports Positive Trial Results for Crofelemer Formulation | JAGX Stock News - GuruFocus
Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases - ACCESS Newswire
Jaguar Health Announces Promising Crofelemer Trial Results - TipRanks
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5%Potential to Modify Disea - Yahoo Finance
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Pre - GuruFocus
Breakthrough Data: New Treatment Hope for Ultra-Rare Pediatric Disease MVIDKey Results Revealed - Stock Titan
Jaguar Health to Present Initial Results from the Proof-of-Conce - GuruFocus
Jaguar Health (JAGX) to Host Webcast on Crofelemer Trials for Ra - GuruFocus
Jaguar Health Schedules Webcast on Crofelemer Trial Results - TipRanks
Breakthrough Clinical Data: New Treatment Hope for Two Ultra-Rare Intestinal Diseases Shows Early Promise - Stock Titan
Form 8-K/ACurrent report: [Amend] - ADVFN
Jaguar Health's (JAGX) Crofelemer Shows Promise in Breast Cancer Subgroup - GuruFocus
Jaguar Health Presents at Elite Ped-GI Congress 2025 - TipRanks
Jaguar Health (JAGX) Reports Progress in Rare Disease Drug Trial - GuruFocus
Jaguar Health's (JAGX) Crofelemer Trial Shows Promise for Rare Disorders | JAGX Stock News - GuruFocus
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress | JAGX Stock News - GuruFocus
First-Ever MVID Treatment? Crucial Trial Data for Orphan Drug Crofelemer Coming to Elite Congress - Stock Titan
Jaguar Health to present results from OnTarget study in breast cancer patients - Yahoo Finance
Jaguar Health to discuss breast cancer treatment with FDA By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Advances OnTarget Study with Key Presentati - GuruFocus
Jaguar Health to discuss breast cancer treatment with FDA - Investing.com
Jaguar Health Announces Significant Results in Breast Cancer Pat - GuruFocus
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting | JAGX Stock News - GuruFocus
Game-Changing Results: New Cancer Drug Shows Remarkable Success in Breast Cancer Patients - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - MSN
Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea - ACCESS Newswire
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting - GuruFocus
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - markets.businessinsider.com
Revolutionary Pain Relief: New FDA-Approved Treatment Transforms Cancer Care Experience - Stock Titan
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer - ACCESS Newswire
Jaguar Health (NASDAQ:JAGX) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World
0.39%
3.66%
자본화:
|
볼륨(24시간):